ライフサイエンスコーパス: prescription drug

1 ty, in addition to objective medical burden (prescription drugs).

2 by all local providers (excluding outpatient prescription drugs).

3 Most older adults use at least one prescription drug.

4 D was associated with increased spending on prescription drugs.

5 mechanism of action of both carcinogens and prescription drugs.

6 nd CYP3A enzymes metabolize more than 50% of prescription drugs.

7 versal access to care, including coverage of prescription drugs.

8 least 10 medications and 23% took at least 5 prescription drugs.

9 lling for age, sex, education, and number of prescription drugs.

10 hat herbs may have harmful interactions with prescription drugs.

11 s, including endogenous steroid hormones and prescription drugs.

12 steroid hormones and xenochemicals including prescription drugs.

13 ity from the unintentional ingestion of oral prescription drugs.

14 street drugs and increasing accessibility to prescription drugs.

15 and may mediate off-target effects of other prescription drugs.

16 5.2%) who were introduced to opioids through prescription drugs (75.0%).

17 patients (median 40 years, 22% males) used a prescription drug (81.5% vs 49.1%).

18 drug screening given a worldwide epidemic of prescription drug abuse and its devastating socioeconomi

19 ems of undertreated pain and the epidemic of prescription drug abuse have coincided, creating a need

20 g Control Policy announced its plan to fight prescription drug abuse in 2011 and unveiled the Risk Ev

21 ctors, comorbidity, depressive symptoms, and prescription drug abuse were also independently associat

22 Direct-to-consumer prescription drug ads typically fail to provide fundamen

23 sults indicate an increase in overall use of prescription drugs among US adults between 1999-2000 and

24 Using prescription drug and medical claims data from a 5% rand

25 fects of step therapy for antidepressants on prescription drug and other medical utilization and spen

26 described in laws that broadly apply to all prescription drugs and biologic products.

27 was linked with National Danish registers on prescription drugs and hospital diagnoses.

28 We compared spending for prescription drugs and other medical care 2 years before

29 cally important exogenous compounds, such as prescription drugs and therapeutic agents.

30 inpatient, outpatient, emergency department, prescription drug, and total all-cause health care expen

31 le for the metabolism of over 50% of current prescription drugs, and cyp3a4 expression is transcripti

32 mit direct-to-consumer advertising (DTCA) of prescription drugs, and many questions remain regarding

33 role in the metabolism of many xenobiotics, prescription drugs, and toxins, we propose that PXR serv

34 n in the preceding week; 50% took at least 1 prescription drug; and 7% took 5 or more.

35 ubstance use disorders involving illicit and prescription drugs are a serious public health issue.

36 ted with the unintentional ingestion of oral prescription drugs are constructed for 1964 through 1992

37 Prescription drugs are instrumental to managing and prev

38 ch and development costs and prices; rather, prescription drugs are priced in the United States prima

39 urements may be helpful in identifying older prescription drugs at higher risk for price change in th

40 ut 460 child deaths from 1974, the year oral prescription drugs became subject to child-resistant pac

41 may be underused or misused in comparison to prescription drugs because of a lack of ongoing postgrad

42 The Medicare Part D prescription drug benefit may facilitate provision of me

43 tion about the effect of the Medicare Part D Prescription Drug Benefit on drug utilization and expend

44 ed will be critical for the affordability of prescription drug benefit programs.

45 ng the first 4 months of the Medicare Part D prescription drug benefit.

46 ts box improved U.S. consumers' knowledge of prescription drug benefits and side effects.

47 associations among cost-sharing features of prescription drug benefits and use of prescription drugs

48 ll as the difficulty in providing affordable prescription drug benefits for older Americans.

49 airs (VA) use different approaches to manage prescription drug benefits, with implications for spendi

50 n exists about the consequences of limits on prescription-drug benefits for Medicare beneficiaries.

51 costs of health care and prescription drugs, prescription-drug benefits for the elderly, the uninsure

52 CT1-interacting ligands in a library of 1780 prescription drugs by combining in silico and in vitro m

53 s not known what effect the increased use of prescription drugs by enrollees in Medicare Part D has h

54 inth Revision, diagnosis for depression or a prescription drug claim for an antidepressant medication

55 inistrative data from hospital discharge and prescription drug claims databases.

56 between hospital discharge, physicians, and prescription drug claims databases.

57 ly spent a much larger fraction of income on prescription drugs compared with those with employer-spo

58 Although the general prescription drug consumer price index grew at 3% per ye

59 Recent changes in US prescription drug cost sharing could affect access to th

60 ed for $2.4 billion in total Medicare part D prescription drug costs and generated the highest percen

61 In response to increasing prescription drug costs, more U.S. patients and policyma

62 onomic status, despite universal coverage of prescription drug costs.

63 et competition, and taking actions to reduce prescription drug costs.

64 th care costs, ED visits, hospital days, and prescription drug costs.

65 e-based formularies in an attempt to control prescription-drug costs.

66 es were identified in adjusted out-of-pocket prescriptions drug costs between the near poor and those

67 id derivatives, a recurring motif in various prescription drugs, could be obtained via a one-pot Stau

68 The impact of Medicare prescription drug coverage (Part D) on CRN is unknown.

69 dicare Part D resulted in increased rates of prescription drug coverage across all economic strata, w

70 or status remained a risk factor for lack of prescription drug coverage after the implementation of M

71 -up of patients, targeted efforts to improve prescription drug coverage among vulnerable beneficiarie

72 the Medicare Part D drug benefit, including prescription drug coverage and risk-adjusted out-of-pock

73 ion of Part D by self-reported generosity of prescription drug coverage before 2006.

74 en born to mothers who were receiving public prescription drug coverage during pregnancy in Ontario,

75 dents of New Jersey aged 65-99 years who had prescription drug coverage either through Medicaid or th

76 Providing full prescription drug coverage for evidence-based pharmacoth

77 orarily stopped taking medication because of prescription drug coverage or management issues, and 18.

78 Cost-sharing in US prescription drug coverage plans for elderly persons var

79 These managers now provide prescription drug coverage to more than 100 million Amer

80 on Medicare beneficiaries who received usual prescription drug coverage under the Part D program live

81 Among respondents under age 65, prescription drug coverage was almost universal, 60% had

82 Those who received prescription drug coverage without deductibles or copaym

83 Compared with current prescription drug coverage, full coverage for post-myoca

84 ohort of patients in the community with full prescription drug coverage, most patients diagnosed with

85 e myocardial infarction (AMI) survivors with prescription drug coverage, of whom 3737 were eligible f

86 nterventions to reduce copayments or improve prescription drug coverage, systems interventions to off

87 s over quality-of-care measures and Medicare prescription drug coverage.

88 to provide beneficiaries with near-universal prescription drug coverage.

89 iciaries with glaucoma who previously lacked prescription drug coverage.

90 in medication adherence among patients with prescription drug coverage.

91 of reduced medication copayments or improved prescription drug coverage.

92 adjusted for differences in supplemental and prescription-drug coverage after 65 years of age.

93 In analyses adjusted for supplemental and prescription-drug coverage, previously uninsured adults

94 Discounts required under California's prescription-drug discount program for Medicare benefici

95 percent of the pharmacies complied with the prescription-drug discount program; at only 45 percent,

96 Several states have developed prescription-drug discount programs for Medicare benefic

97 003 were identified using linked data on all prescription drug dispensings, physician services, and h

98 icacious, and cost-effective to use Medicare prescription drug dollars to provide full coverage for l

99 tabases may be valuable tools for evaluating prescription drug effects on all major outcomes of clini

100 High prescription drug expenditures are likely to continue to

101 mated $592 billion (a 38% increase over 2015 prescription drug expenditures).

102 substitution is one mechanism of curtailing prescription drug expenditures.

103 s that could be defined using both ICD-9 and prescription drug fill codes, prevalence was higher befo

104 Diseases, Ninth Revision [ICD-9] codes) and prescription drug fills.

105 tabolizer genotype; no nicotine for 6 weeks, prescription drugs for 4 weeks, over-the-counter drugs f

106 zation Act was intended to improve access to prescription drugs for millions of seniors, by providing

107 114 stand-alone and 2,230 Medicare Advantage prescription drug formularies, which represent all formu

108 Large-scale prescription drug importation is currently illegal, but

109 Since the introduction of the Medicare Prescription Drug Improvement and Modernization Act and

110 The Medicare Prescription Drug, Improvement, and Modernization Act (M

111 The Medicare Prescription Drug, Improvement, and Modernization Act of

112 The Medicare Prescription Drug, Improvement, and Modernization Act of

113 imated 51% of US adults reporting use of any prescription drugs in 1999-2000 and an estimated 59% rep

114 ion on direct-to-consumer advertisements for prescription drugs in 1999.

115 00 and an estimated 59% reporting use of any prescription drugs in 2011-2012 (difference, 8% [95% CI,

116 of complete information about the benefit of prescription drugs in advertisements would serve the int

117 ue of safe use of nonprescription as well as prescription drugs in patients with underlying liver dis

118 l health conditions, smoking, and use of non-prescription drugs in the past year in both sexes, and w

119 Within each NHANES cycle, use of prescription drugs in the prior 30 days was assessed ove

120 The increasing cost of prescription drugs in the United States has become a sou

121 hysicians to address the escalating costs of prescription drugs in the United States.

122 NET is a known target for a variety of prescription drugs, including antidepressants and psycho

123 The prevalence of polypharmacy (use of >/=5 prescription drugs) increased from an estimated 8.2% in

124 gests that direct-to-consumer advertising of prescription drugs increases pharmaceutical sales and bo

125 rmaceutical assistance program that provides prescription drug insurance for elderly persons.

126 Potential herb-prescription drug interactions are not just limited to S

127 Spending on prescription drugs is the fastest growing component of t

128 hanger of amino acids, thyroid hormones, and prescription drugs--is highly expressed in the blood-bra

129 Generic prescription drugs made by different manufacturers may v

130 s, beginning in the 1940s when growth in the prescription drug market fueled industry interest in und

131 gents are the fastest-growing segment of the prescription drug market.

132 gists and industry employees relative to the Prescription Drug Marketing Act or the False Claims Act

133 m), each pled guilty to one violation of the Prescription Drug Marketing Act, settled claims related

134 ge, male sex, IADL disability, and number of prescription drugs measured at baseline were significant

135 pread implementation of illicit drug use and prescription drug misuse screening and brief interventio

136 equent alcohol use, frequent binge drinking, prescription drug misuse, and over-the-counter drug misu

137 brief intervention for illicit drug use and prescription drug misuse, based in part on evidence of e

138 s first identification, to our knowledge, of prescription drugs modifying the regulation of cathepsin

139 vel data derived from California's statewide prescription drug monitoring program (PDMP) and county-l

140 every 3 months or more frequently and review prescription drug monitoring program data, when availabl

141 tests, monitoring pill counts, and reviewing prescription drug monitoring program data, when availabl

142 onal study using data from medical examiner, prescription drug monitoring program, and opiate treatme

143 ordinated care possible, states have created prescription drug monitoring programs to collect records

144 Other resources, such as state-run prescription drug monitoring programs, are also availabl

145 n 120 mg did not decline after adoption of a prescription-drug monitoring program (0.27 percentage po

146 012) and an original data set of laws (e.g., prescription-drug monitoring programs), we examined the

147 of the FPL) and (2) cost-sharing levels for prescription drugs, office visits, and emergency departm

148 Communication about prescription drugs ought to be a paragon of public scien

149 trols for changes in the consumption of oral prescription drugs over time and for long-term safety tr

150 nrollment versus nonenrollment in Medicare's prescription drug plan (Part D) is associated with bette

151 the source population of Medicare Advantage Prescription Drug plan beneficiaries, 8% entered the cov

152 We used the Medicare July 2014 Prescription Drug Plan Formulary, Pharmacy Network, and

153 ne or pioglitazone through a Medicare Part D prescription drug plan from July 2006-June 2009 and who

154 re beneficiaries who enrolled in a state-run prescription drug plan that fully covered NSAIDs and cox

155 Prescription drugs play an important part in treating an

156 g in the biological samples (5.6%), although prescription drugs (prescription pain pills, sedatives,

157 for voters were the costs of health care and prescription drugs, prescription-drug benefits for the e

158 olicy changes enabling Medicare to negotiate prescription drug prices could decrease costs to Medicar

159 ected by > 80% of participants: cancer care, prescription drugs, primary care, home care, palliative

160 l patient registry, cause of death registry, prescription drug registry, and education and income reg

161 ociated with an annual reduction in the oral prescription drug-related mortality rate of 1.40 (95% co

162 elationship between the availability of free prescription drug samples and dermatologists' prescribin

163 For problem use of illicit and prescription drugs, sensitivity ranged from 0.82 (CI, 0.

164 rating SEs extracted from package inserts of prescription drugs, SEs extracted from FDA Adverse Event

165 mbia (2004-2011), which include health care, prescription drugs, sociodemographic, and mortality info

166 For each 10% increase in cost sharing, prescription drug spending decreases by 2% to 6%, depend

167 Per capita prescription drug spending in the United States exceeds

168 valent to brand-name drugs, can help contain prescription drug spending.

169 talyzes the covalent modification of certain prescription drugs such as the commonly used steroid, pr

170 edication error or evaluate patients' actual prescription drug-taking behaviors.

171 , the United States often pays more for some prescription drugs than other developed countries, and t

172 Here, we identify prescription drugs that bind NET, using virtual ligand s

173 ffer chemically from another-and, unlike for prescription drugs, there are no databases linking herb

174 gh reference pricing may reduce the costs of prescription drugs, there is concern that patients may s

175 ending on direct-to-consumer advertising for prescription drugs tripled between 1996 and 2000, when i

176 ources of regional variation in spending for prescription drugs under Medicare Part D are poorly unde

177 calculated prevalence ratios (PRs) comparing prescription drug use 36 months after RYGB/index date wi

178 Evaluation of prescription drug use among elderly persons by type of h

179 ive survey, significant increases in overall prescription drug use and polypharmacy were observed.

180 A little is known about the prescription drug use before and after RYGB surgery.

181 might be accurate for timing first-trimester prescription drug use in automated databases.

182 The prevalence of prescription drug use increased in the majority of, but

183 lso reported positive outcomes in nonmedical prescription drug use occasions.

184 methods of data collection to understand the prescription drug use problem.

185 It is important to document patterns of prescription drug use to inform both clinical practice a

186 Prescription drug use was estimated for lipid-modifying

187 Temporal trends in prescription drug use were evaluated using nationally re

188 not differ significantly in inpatient care, prescription drug use, or number of emergency department

189 icare data for 4.7 million beneficiaries for prescription-drug use and expenditures overall and in th

190 res of prescription drug benefits and use of prescription drugs, use of nonpharmaceutical services, a

191 The Prescription Drug User Fee Act (PDUFA) imposes deadlines

192 The upcoming reauthorization of the Prescription Drug User Fee Act focuses on improving the

193 Among prescription drug users, 16% also took an herbal/supplem

194 In 2013, per capita spending on prescription drugs was $858 compared with an average of

195 ending for promotional purposes and sales of prescription drugs, we examined industrywide trends for

196 , while being employed and nonmedical use of prescription drugs were associated with binge drinking c

197 For both men and women and at all ages, prescription drugs were involved in more deaths than wer

198 to treat health problems without doctors or prescription drugs were more likely to prefer an annual

199 e in cells stably expressing MATE1, over 900 prescription drugs were screened and 84 potential MATE1

200 ly on other countries as sources of imported prescription drugs: whether the safety of the product ca

201 ility that direct-to-consumer advertising of prescription drugs will result in inappropriate prescrib

202 suffer from dry mouth as a result of taking prescription drugs, with an apparent concomitant increas

203 Although the year 2001 did not see any prescription drugs withdrawn because of drug-induced liv

204 al diversion, defined as a death involving a prescription drug without a documented prescription and